Iqvia Hldgs (IQV) Stock News

IQVIA (NYSE:IQV) and Duke Clinical Research Institute (DCRI) announced a strategic collaboration on February 10, 2026 to accelerate clinical research in obesity and related cardiometabolic conditions. The partnership combines IQVIA operational scale and real-world data with DCRI academic trial design and execution.

Key capabilities include access to patients across 56 countries and >3,000 sites, IQVIA’s experience with >120 obesity trials and >90,000 patients enrolled, and combined analytics, biostatistics and AI-enabled trial execution to support faster, more representative studies and regulatory submissions.

IQVIA (NYSE:IQV) reported fourth-quarter 2025 revenue of $4,364M and full-year revenue of $16,310M, with fourth-quarter GAAP net income of $514M and full-year GAAP net income of $1,360M. Adjusted diluted EPS was $3.42 Q4 and $11.92 full-year. R&DS backlog totaled $32.7B and quarterly R&DS bookings exceeded $2.7B (book-to-bill 1.18x). Operating cash flow was $735M Q4 and $2,654M full-year; free cash flow was $561M Q4 and $2,051M full-year. Full-year 2026 guidance: revenue $17,150–17,350M, Adjusted EBITDA $3,975–4,025M, Adjusted diluted EPS $12.55–12.85.

IQVIA (NYSE:IQV) announced a strategic, long-term collaboration with Boehringer Ingelheim to use IQVIA’s Data-as-a-Service (DaaS+) platform as the accelerator for global commercial data harmonization and transformation.

The deal targets harmonized market, brand and franchise reporting across 59 countries, cloud-native ingestion, global product mastering, and aims to support upcoming launches, improve market performance and enable AI-powered analytics.

IQVIA (NYSE:IQV) was named No. 1 in the Health Care: Pharmacy and Other Services category on the 2026 Fortune® World’s Most Admired Companies™ list.

This marks IQVIA's fifth consecutive year at No. 1 in its sector and its ninth consecutive year on the list. IQVIA ranked first in seven of nine evaluated attributes, including innovation, people management, use of corporate assets, financial soundness, long-term investment value, quality of products/services, and global competitiveness. Fortune and Korn Ferry analyzed 685 companies and surveyed more than 3,000 executives for the annual reputational ranking.

IQVIA (NYSE:IQV) will announce its fourth-quarter and full-year 2025 financial results before market open on Thursday, February 5, 2026. Management will host a conference call and live webcast at 9:00 a.m. Eastern Time the same day. The earnings release, financial information and presentation slides will be posted on the IQVIA Investor Relations site (http://ir.iqvia.com). Interested parties must register in advance to join the conference call; registrants receive a confirmation email with dial-in, unique passcode and registrant ID. A replay of the webcast will be available about two hours after the live event on the investor site.

IQVIA (NYSE: IQV) announced a strategic collaboration with Amazon Web Services (AWS) on December 2, 2025, naming AWS as IQVIA's Preferred Agentic Cloud Provider.

IQVIA will deploy its agentic AI platform on AWS to support scalable, secure automation across clinical trial execution, medical affairs, and healthcare analytics. The companies said they will explore additional life‑sciences analytics opportunities and aim to democratize AI to accelerate drug innovation.

The release notes that 90% of the world’s largest pharmaceutical companies rely on both IQVIA and AWS to power digital transformation and analytics.

IQVIA (NYSE:IQV) announced that Dr. William G. Kaelin Jr. joined its board of directors effective November 5, 2025.

Dr. Kaelin is a Nobel Prize winner in Physiology or Medicine (2019), a Senior Physician-Scientist at Brigham and Women’s Hospital, Sidney Farber Professor of Medicine at Dana-Farber and Harvard Medical School, and an Investigator at the Howard Hughes Medical Institute. He serves on the board of Eli Lilly and chairs its Science and Technology Committee. Dr. Kaelin is an author on hundreds of peer-reviewed publications and holds multiple patents in cancer biology and hypoxia signaling.

NEXT Oncology (IQV) expanded into Japan via a joint venture partnership with Kansai Medical University in Osaka on November 5, 2025. Kansai will offer Phase I oncology trials as part of the NEXT Oncology global network under Director Dr. Toshio Shimizu, who trained in early Phase I drug development with NEXT’s CEO Dr. Anthony W. Tolcher. The Osaka site joins locations across the U.S., Spain, and Brazil. NEXT Oncology treats more than 1,000 patients per year, and the partnership adds Japanese patient access to first‑in‑human and Phase I programs.

IQVIA (NYSE:IQV) reported Q3 2025 revenue of $4,100 million, up 5.2% year‑over‑year (3.9% at constant currency), and GAAP net income of $331 million with GAAP diluted EPS of $1.93.

Adjusted results included Adjusted EBITDA $949 million, Adjusted diluted EPS $3.00, and free cash flow $772 million (up 35% YoY). R&D Solutions reported $2.6 billion in quarterly bookings (book‑to‑bill 1.15x) and a contracted backlog of $32.4 billion. Operating cash flow was $908 million. Net debt totaled $13,143 million and net leverage was 3.52x. The company reaffirmed full‑year 2025 guidance and narrowed ranges on revenue, Adjusted EBITDA, and Adjusted EPS.